156 related articles for article (PubMed ID: 35285087)
1. Omaveloxolone attenuates squamous cell carcinoma growth and disease severity in an Epidermolysis Bullosa mouse model.
Cohen-Nowak AJ; Cohen AJ; Correia ED; Portocarrero CP; South AP; Nikbakht N
Exp Dermatol; 2022 Jul; 31(7):1083-1088. PubMed ID: 35285087
[TBL] [Abstract][Full Text] [Related]
2. Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.
Bonamonte D; Filoni A; De Marco A; Lospalluti L; Nacchiero E; Ronghi V; Colagrande A; Giudice G; Cazzato G
Cells; 2022 Apr; 11(8):. PubMed ID: 35456044
[TBL] [Abstract][Full Text] [Related]
3. Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: report of 7 cases and a review of the literature.
Yuen WY; Jonkman MF
J Am Acad Dermatol; 2011 Oct; 65(4):780-789. PubMed ID: 21624701
[TBL] [Abstract][Full Text] [Related]
4. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006.
Fine JD; Johnson LB; Weiner M; Li KP; Suchindran C
J Am Acad Dermatol; 2009 Feb; 60(2):203-11. PubMed ID: 19026465
[TBL] [Abstract][Full Text] [Related]
5. The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry.
Harrs C; van den Akker PC; Baardman R; Duipmans JC; Horváth B; van Kester MS; Lemmink HH; Rácz E; Bolling MC; Diercks GFH
Br J Dermatol; 2022 Nov; 187(5):824-826. PubMed ID: 35830206
[No Abstract] [Full Text] [Related]
6. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.
Welponer T; Weber DD; Trattner L; Tockner B; Aminzadeh-Gohari S; Leb-Reichl V; Kaufmann A; Zauner R; Wimmer M; Wally V; Felder TK; Strunk D; Koller U; Bauer JW; Kofler B; Guttmann-Gruber C; Piñon Hofbauer J
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):112-123. PubMed ID: 37669776
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.
Robertson SJ; Orrin E; Lakhan MK; O'Sullivan G; Felton J; Robson A; Greenblatt DT; Bernardis C; McGrath JA; Martinez AE; Mellerio JE
Acta Derm Venereol; 2021 Aug; 101(8):adv00523. PubMed ID: 34230977
[TBL] [Abstract][Full Text] [Related]
8. Surgical treatment and management of cutaneous squamous cell carcinoma in patients with dystrophic epidermolysis bullosa - a case report.
Rotschein P; Vokurková J; Bučková H
Acta Chir Plast; 2021; 63(4):196-200. PubMed ID: 35042364
[TBL] [Abstract][Full Text] [Related]
9. Electrochemotherapy, a local treatment for squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
Bartolo J; Farricha V; Carvalhal S; Moura C; Abecasis N
Dermatol Ther; 2020 Nov; 33(6):e14093. PubMed ID: 32720460
[TBL] [Abstract][Full Text] [Related]
10. Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.
Condorelli AG; Dellambra E; Logli E; Zambruno G; Castiglia D
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739489
[TBL] [Abstract][Full Text] [Related]
11. Treatment of skin cancers in epidermolysis bullosa.
Venugopal SS; Murrell DF
Dermatol Clin; 2010 Apr; 28(2):283-7, ix-x. PubMed ID: 20447493
[TBL] [Abstract][Full Text] [Related]
12. Age and etiology of childhood epidermolysis bullosa mortality.
Hon KL; Li JJ; Cheng BL; Luk DC; Murrell DF; Choi PC; Leung AK
J Dermatolog Treat; 2015 Apr; 26(2):178-82. PubMed ID: 24724596
[TBL] [Abstract][Full Text] [Related]
13. Epidermolysis bullosa complicated by squamous cell carcinoma: report of 10 cases.
McGrath JA; Schofield OM; Mayou BJ; McKee PH; Eady RA
J Cutan Pathol; 1992 Apr; 19(2):116-23. PubMed ID: 1597567
[TBL] [Abstract][Full Text] [Related]
14. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl.
Shivaswamy KN; Sumathy TK; Shyamprasad AL; Ranganathan C
Int J Dermatol; 2009 Jul; 48(7):731-3. PubMed ID: 19570079
[TBL] [Abstract][Full Text] [Related]
15. The potential of gene therapy for recessive dystrophic epidermolysis bullosa.
Subramaniam KS; Antoniou MN; McGrath JA; Lwin SM
Br J Dermatol; 2022 Apr; 186(4):609-619. PubMed ID: 34862606
[TBL] [Abstract][Full Text] [Related]
16. Epidermolysis bullosa and cancer.
Mallipeddi R
Clin Exp Dermatol; 2002 Nov; 27(8):616-23. PubMed ID: 12472531
[TBL] [Abstract][Full Text] [Related]
17. Expression and glycosylation of MUC1 in epidermolysis bullosa-associated and sporadic cutaneous squamous cell carcinomas.
Cooper HL; Cook IS; Theaker JM; Mallipeddi R; McGrath J; Friedmann P; Healy E
Br J Dermatol; 2004 Sep; 151(3):540-5. PubMed ID: 15377338
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand.
Kim M; Li M; Intong-Wheeler LRA; Tran K; Marucci D; Murrell DF
Acta Derm Venereol; 2018 Jan; 98(1):70-76. PubMed ID: 28853495
[TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa.
Weber F; Bauer JW; Sepp N; Högler W; Salmhofer W; Hintner H; Fritsch P
Acta Derm Venereol; 2001; 81(3):189-92. PubMed ID: 11558875
[TBL] [Abstract][Full Text] [Related]
20. Ultrastructural findings in epidermolysis bullosa.
Smith LT
Arch Dermatol; 1993 Dec; 129(12):1578-84. PubMed ID: 7504435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
